Allarity Therapeutics Inc is a clinical-stage, precision medicine company. Allarity Therapeutics Inc is a clinical-stage, precision medicine company.
Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancerAllarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparib’s...
Cash balance at $18.5 millionStrengthened leadership team with new members driving stenoparib developmentNASDAQ compliance regained Boston (November 14, 2024)—Allarity Therapeutics, Inc...
European Patent Office to grant a patent for DRP® companion diagnostic for Allarity’s stenoparib cancer therapy Patent applications for the Stenoparib DRP® are also pending in the US, Japan...
Boston (October 10, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.22 | -17.3228346457 | 1.27 | 1.29 | 1.04 | 244470 | 1.11930965 | CS |
4 | -0.38 | -26.5734265734 | 1.43 | 1.53 | 1.04 | 238599 | 1.27922719 | CS |
12 | -3.135 | -74.9103942652 | 4.185 | 4.194 | 1.04 | 714787 | 2.3039469 | CS |
26 | -16.74 | -94.0978077572 | 17.79 | 18.642 | 1.04 | 3172423 | 6.00862676 | CS |
52 | -383.25 | -99.7267759563 | 384.3 | 666 | 1.04 | 3013811 | 58.37442674 | CS |
156 | 250334.839414 | -100.00041944 | -250333.789414 | 92640 | -167332.373652 | 1872772 | 1414.7257566 | CS |
260 | 250334.839414 | -100.00041944 | -250333.789414 | 92640 | -167332.373652 | 1872772 | 1414.7257566 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales